Your browser doesn't support javascript.
loading
Radiation Therapy Dose Response in Bulky Relapsed/Refractory Large B-Cell Lymphoma.
Baron, Jonathan A; Wright, Christopher M; Dreyfuss, Alexandra D; Chong, Elise A; Svoboda, Jakub; LaRiviere, Michael J; Jones, Joshua A; Maity, Amit; Plastaras, John P; Paydar, Ima; Maxwell, Russell.
Affiliation
  • Baron JA; Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: baronjo@pennmedicine.upenn.edu.
  • Wright CM; Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; Radiation Oncology Associates, Burlington, Massachusetts.
  • Dreyfuss AD; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Chong EA; Department of Hematology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
  • Svoboda J; Department of Hematology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
  • LaRiviere MJ; Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
  • Jones JA; Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
  • Maity A; Department of Radiation Oncology, Huntsman Cancer Institute and University of Utah Health, Salt Lake City, Utah Health.
  • Plastaras JP; Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
  • Paydar I; Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
  • Maxwell R; Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Pract Radiat Oncol ; 2024 Jul 04.
Article in En | MEDLINE | ID: mdl-38971218
ABSTRACT

PURPOSE:

To assess whether a radiation therapy (RT) dose affects response in bulky tumors in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). METHODS AND MATERIALS Data from patients with r/r DLBCL treated with salvage- or palliative-intent RT (2008-2020) at a single institution were examined. Index lesion size ≥7.5 cm was defined as bulky. Equivalent doses in 2-Gy fractions (EQD2) were calculated to compare doses between conventional and hypofractionated (≥2.5 Gy/fraction) schemes. Objective response rates (ORRs) were compared using nonparametric Mann-Whitney U test or Kruskal-Wallis test with Dunn's multiple comparison corrections. Freedom from local progression (FFLP) was assessed using Kaplan-Meier and Cox proportional hazard regression analyses.

RESULTS:

One hundred eighty-three courses of 151 unique patients were included (salvage 37% and palliative 63%). Nonbulky and bulky tumors were irradiated in 109 (60%) and 74 (40%) courses, respectively. Median EQD2 was 33 Gy (IQR, 23-39 Gy) with hypofractionation in 84 (46%) cases. Of those with post-RT imaging (80%), the ORR was 59%, with a trend toward worsened ORR in bulky tumors (50% vs 65%, P = .077). For bulky tumors, RT regimens with EQD2s >30 Gy were associated with better ORR (≤30 Gy vs >30 Gy 27% vs 64%, P = .0073), whereas a lower EQD2 cutoff was sufficient for nonbulky tumors (≤20 Gy vs >20 Gy 38% vs 75%, P = .0011). On multivariable regression analysis, bulky tumor size was associated with worsened FFLP (hazard ratio, 2.07; 95% CI, 1.16-3.68; P = .014), whereas high EQD2s >30 Gy were associated with better FFLP (hazard ratio, 0.48; 95% CI, 0.25-0.93; P = .031). Bulky tumors treated with EQD2s ≤30 Gy had the lowest median FFLP (4.0 months), whereas EQD2s >30 Gy had an unreached median FFLP (P = .0047).

CONCLUSIONS:

Bulky r/r DLBCL tumors were associated with less favorable tumor control outcomes in the salvage and palliative settings. RT regimens with higher EQD2s (>30 Gy) should be considered if durable local control of bulky tumors is desired.

Full text: 1 Database: MEDLINE Language: En Journal: Pract Radiat Oncol Year: 2024 Type: Article

Full text: 1 Database: MEDLINE Language: En Journal: Pract Radiat Oncol Year: 2024 Type: Article